Increasing Prevalence Of Lyme Disease Fueling The Growth Of The Market Due To Climate-Driven Expansion Of Tick Habitats Is Supporting Development Across The Lyme Disease Vaccine Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Lyme Disease Vaccine Market Compare Between 2026 And 2030?

The lyme disease vaccine market has shown robust expansion in recent years. Its size is projected to increase from $1.12 billion in 2025 to $1.2 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to several factors, including the increasing incidence of lyme disease in endemic regions, past limitations of antibiotic-only treatment approaches, early-stage vaccine research initiatives, growing awareness of tick-borne infections, and improvements in public health surveillance.

The lyme disease vaccine market is projected for substantial expansion over the next few years. Its valuation is anticipated to reach $1.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected increase during the forecast period is driven by factors such as the broadening of vaccination programs in endemic regions, a rise in investment dedicated to infectious disease prevention, advancements in next-generation vaccine platforms, an increasing adoption of combination vaccines, and a growing global emphasis on controlling zoonotic diseases. Notable trends expected in this period include improvements in recombinant vaccine technologies, a greater focus on preventive immunization initiatives, an expansion of clinical research concerning tick-borne diseases, a stronger emphasis on solutions providing long-lasting immunity, and increased collaboration between public and private health organizations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

What Influential Factors Are Boosting The Lyme Disease Vaccine Market Demand?

The expanding occurrence of Lyme disease is anticipated to boost the Lyme disease vaccine market in the future. Lyme disease, an infection transmitted by ticks, is caused by Borrelia bacteria, manifesting as fever, fatigue, rashes, and potentially severe issues with joints, the heart, or nerves if not treated. The heightened incidence of Lyme disease stems from climate change, as warmer climates and less severe winters extend tick habitats, consequently increasing human contact with infected ticks. Lyme disease vaccines contribute to preventing the disease by preparing the immune system to identify and combat Borrelia bacteria, thereby lowering infection risks. They streamline disease management through sustained protection, which enhances overall public health. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based federal health agency, in 2023, around 89,000 cases of Lyme disease were reported in the United States, while estimates using other methods suggest that approximately 476,000 people may be diagnosed and treated for Lyme disease each year. Consequently, the rising prevalence of Lyme disease is propelling the expansion of the Lyme disease vaccine market.

How Is The Lyme Disease Vaccine Market Structured Across Different Market Segments?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

What Trends Are Affecting The Lyme Disease Vaccine Market Dynamics?

Companies operating in the Lyme disease vaccine market are focusing on advancing their late-stage product candidates, such as booster vaccines, to address unmet medical needs, enhance immune protection, and simplify vaccination regimens. Booster vaccines are additional doses administered after the initial vaccination to restore or augment long-term immunity. For instance, in September 2025, Valneva SE, a France-based biotechnology company, confirmed positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine that trains the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies block the bacteria inside the tick, preventing infection in humans. The strong immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving previous annual booster doses, further demonstrating compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. This booster strategy is intended to provide continued protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.

Who Are The Firms Contributing To The Lyme Disease Vaccine Market Ecosystem?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Access The Complete Lyme Disease Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Geographic Region Represents The Largest Lyme Disease Vaccine Market Share?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lyme Disease Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795